

Wenjie Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3867225/publications.pdf>

Version: 2024-02-01

29
papers

592
citations

687363
13
h-index

642732
23
g-index

30
all docs

30
docs citations

30
times ranked

677
citing authors

#	ARTICLE	IF	CITATIONS
1	Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation. International Journal of Biological Sciences, 2022, 18, 1022-1038.	6.4	17
2	Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 629327.	2.8	11
3	DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination. Cell and Bioscience, 2021, 11, 42.	4.8	30
4	Biological testing of chitosanâ€collagenâ€based porous scaffolds loaded with PLGA/Triamcinolone microspheres for ameliorating endoscopic dissectionâ€related stenosis in oesophagus. Cell Proliferation, 2021, 54, e13004.	5.3	6
5	Rac Family Small GTPase 3 Correlates with Progression and Poor Prognosis in Bladder Cancer. DNA and Cell Biology, 2021, 40, 469-481.	1.9	5
6	USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638. Cell Death and Disease, 2020, 11, 843.	6.3	19
7	Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. Cell and Bioscience, 2020, 10, 127.	4.8	51
8	Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 604766.	3.5	41
9	Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3Î²/Î²-catenin axis. Journal of Translational Medicine, 2020, 18, 81.	4.4	33
10	Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Current Medicinal Chemistry, 2020, 27, 3290-3301.	2.4	5
11	The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma. Current Medicinal Chemistry, 2020, 28, 93-109.	2.4	23
12	Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma. Current Molecular Pharmacology, 2020, 13, 261-272.	1.5	14
13	Organoid: Current Implications and Pharmaceutical Applications in Liver Diseases. Current Molecular Pharmacology, 2020, 13, 498-508.	1.5	1
14	Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma. Mini-Reviews in Medicinal Chemistry, 2020, 20, 1153-1165.	2.4	3
15	B7-H3 participates in human salivary gland epithelial cells apoptosis through NF-Î²B pathway in primary Sjögrenâ€™s syndrome. Journal of Translational Medicine, 2019, 17, 268.	4.4	27
16	Circulating Exosomes Derived-miR-146a from Systemic Lupus Erythematosus Patients Regulates Senescence of Mesenchymal Stem Cells. BioMed Research International, 2019, 2019, 1-10.	1.9	44
17	Exosomal microRNAâ€155â€5p from PDLSCs regulated Th17/Treg balance by targeting sirtuinâ€1 in chronic periodontitis. Journal of Cellular Physiology, 2019, 234, 20662-20674.	4.1	108
18	Oncogenic Wnt3a: A Candidate Specific Marker and Novel Molecular Target for Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 5862-5873.	2.5	20

#	ARTICLE	IF	CITATIONS
19	Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma. Disease Markers, 2019, 2019, 1-13.	1.3	14
20	Loss of BMP-10 is correlated with poor survival in ovarian cancer. Pathology Research and Practice, 2019, 215, 121-126.	2.3	3
21	Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy. Mini-Reviews in Medicinal Chemistry, 2019, 19, 272-280.	2.4	7
22	Effects of Extracellular Vesicles Derived from Mesenchymal Stem/Stromal Cells on Liver Diseases. Current Stem Cell Research and Therapy, 2019, 14, 442-452.	1.3	7
23	Role of secretory clusterin in hepatocarcinogenesis. Translational Gastroenterology and Hepatology, 2018, 3, 48-48.	3.0	14
24	High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma. Cancer Management and Research, 2018, Volume 10, 5979-5989.	1.9	13
25	Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget, 2017, 8, 52321-52332.	1.8	16
26	Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. BioScience Trends, 2016, 10, 337-343.	3.4	14
27	Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. Tumor Biology, 2016, 37, 5561-5568.	1.8	13
28	Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. Tumor Biology, 2016, 37, 999-1008.	1.8	17
29	Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells. Tumor Biology, 2015, 36, 3995-4003.	1.8	16